Kyntra Bio (KYNB) Change in Accured Expenses (2014 - 2026)

Kyntra Bio has reported Change in Accured Expenses for 13 years, with the latest figure at -$2.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 92.26% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 80.21% YoY) and the FY2025 annual result came in at -$53.5 million, up 42.96% from the prior year.
• Change in Accured Expenses rose to -$2.5 million in Q1 2026 per KYNB's latest filing, from -$5.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $66.0 million in Q1 2022 and troughed at -$76.7 million in Q4 2024.
• A 5-year average of -$5.6 million and a median of $468000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 22546.6% in 2022, then plunged 16484.19% in 2024.
• Over 5 years, Change in Accured Expenses stood at $3.4 million in 2022, then slumped by 86.19% to $468000.0 in 2023, then slumped by 16484.19% to -$76.7 million in 2024, then surged by 93.02% to -$5.3 million in 2025, then surged by 54.14% to -$2.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$2.5 million, -$5.3 million, and -$17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.